William Rosenfeld
Neurology · Chesterfield, MONPI 1851413587
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,847,078 of the $2,133,376 with a category attached, or 86.6%. SK Life Science, Inc. accounts for 99.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $484,926 and has fallen 71.8% since, to $136,730 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 452 payments — averaging $4719.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$2.1M
- Greenwich Biosciences, Inc.$6K
- UCB, Inc.$150
- Jazz Pharmaceuticals Inc.$84
- Neurelis, Inc.$72
- Assertio Therapeutics, Inc.$27
Across 29 payments — averaging $10,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$156K
- SK Life Science, Inc.$116K
- GW Research Limited$21K
- UCB Biosciences Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- UCB SA$14
What the payments were for
- Consulting fees$1,847,07887%
- Speaking & faculty fees$246,62512%
- Travel & lodging$31,2231%
- Food & beverage$8,3790%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 436 | $2,126,626 |
| Greenwich Biosciences, Inc. | 10 | $6,417 |
| UCB, Inc. | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 1 | $84 |
| Neurelis, Inc. | 2 | $72 |
| Assertio Therapeutics, Inc. | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$2,113,592
- Cenobamate$7,815
- Epidiolex$6,317
How this compares
$2,133,376 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 13 | $3,323 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chesterfield
- Barbara GreenChesterfield$352K
- Max BenzaquenChesterfield$105K
- Emily EvansChesterfield$60K
- Zaheer AhmedChesterfield$20K
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.